Skip to main content
Equibles
RGBP logo

RGBP · Regen BioPharma Inc · Metrics

Track RGBP — free

Use RGBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.”
View the 10-Q filed Aug 17, 2026
Market Cap
$335,055
Shares
1.68B
Volume · Nov 6 3.62M Avg daily vol (3M) 7.96M

RGBP metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$335,055

Price action

23 metrics
Price change (1W)
+100.0%
Price change (30D)
+100.0%
Price change (3M)
+0.0%
Price change (6M)
-33.3%
Price change (YTD)
-97.3%
Price change (1Y)
-98.0%
Trailing year
Price change (5Y)
—
52-week high
$0.01
52-week low
$0.00
Change from 52-week high
-98.3%
Change from 52-week low
+100.0%
Annualized volatility
525.3%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
5.2
RSI (14D)
59.7
Price vs SMA 50
+63.9%
Price vs SMA 200
-79.7%
Avg volume (3M)
7.94M
Relative volume
0.1
Average dollar volume
$856

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.68B

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 40,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 70.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-354.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-339.8%
Trailing 12 months
Net margin
-501.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$803,862
Net income (TTM)
−$1.19M
Trailing 12 months
Diluted EPS (TTM)
$0.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.16

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$236,561
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,491.5%
Year over year · more shares
Revenue CAGR (3Y)
+23.5%
Revenue CAGR (5Y)
+16.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-412.5%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-4.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$239
Total assets
$287,587
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$445,249
Capital expenditures (TTM)
—
R&D (TTM)
$223,941
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
94.7%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
22 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1589150 CUSIP 75886M300 Visit website Investor relations